Welcome Guest
Home > Clinical Breast Cancer > Volume 3 |  Issue 2

Table of Contents

Volume 3 |  Issue 2

Publication Date: June 2002
  • Abstract Abstract
  • Full Text No Access
  • Full Text Pay-Per View
  • Full Text Full Text
  • Add to Cart Add to Cart


Editorial
Page Number of this Article in the Print Version
91		 Can We Afford to Cure?
George W. Sledge, Jr
  • Abstract
  • No Access
  • Add to Cart
Meeting Highlights
Page Number of this Article in the Print Version
94-98		 Highlights From: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 18-21, 2002
Amy I. D’Orazio, Joyce O’Shaughnessy
  • Abstract
  • No Access
  • Add to Cart
Researches in Brief
Page Number of this Article in the Print Version
103-105		 Improvement in Disease-Free Survival with Doxorubicin/Docetaxel/Cyclophosphamide (TAC) Versus 5-Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) as Adjuvant Therapy for Node-Positive Breast Cancer
Amy I. D’Orazio, Joyce O’Shaughnessy
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
106-108		 Activity of Tipifarnib (R115777, Zarnestra™), a Farnesyl Transferase Inhibitor, in Previously Treated Metastatic Breast Cancer
Kavita Maung, Vinay K. Jain
  • Abstract
  • No Access
  • Add to Cart
Comprehensive Reviews
Page Number of this Article in the Print Version
113-124		 Breast Cancer Chemoprevention: Current Challenges and a Look Toward the Future
Carol J. Fabian, and Bruce F. Kimler
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
125-135		 The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
Raquel Andrade Nunes, Lyndsay N. Harris
  • Abstract
  • No Access
  • Add to Cart
Commentary
Page Number of this Article in the Print Version
136-137		 Is There a Role for Monitoring Circulating HER2?
Daniel F. Hayes
  • Abstract
  • No Access
  • Add to Cart
Original Contributions
Page Number of this Article in the Print Version
138-146		 Prognostic Value of the Urokinase-Type Plasminogen Activator, and its Inhibitors and Receptor in Breast Cancer Patients
S. Borstnar, I. Vrhovec, B. Svetic, Tanja Cufer
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
147-152		 Adjuvant Chemotherapy with Doxorubicin and Cyclophosphamide in Women with Rapidly Proliferating Node-Negative Breast Cancer
Stephen E. Jones, Gary Clark, Sherry Koleszar, Gaby Ethington, Robert Mennel, Steven Paulson, Barry Brooks, Ronald Kerr, Claude Denham, Michael Savin, Joanne Blum, Robert Kirby, Marvin Stone, John Pippen, Timothy George, Douglas Orr, Sally Knox, Michael Grant, George Peters, Daniel Savino, Charles Rietz
  • Abstract
  • No Access
  • Add to Cart
Current Trial
Page Number of this Article in the Print Version
153-159		 The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial
Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin, Norman Wolmark
  • Abstract
  • No Access
  • Add to Cart